The introduction of HER2-directed monoclonal antibodies, such as trastuzumab and pertuzumab, transformed the therapeutic landscape of HER2-positive breast cancer by blocking receptor activation and dimerization. This evidence concerns the gene ERBB2 and breast carcinoma.